---
title: "Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290479467.md"
description: "Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on June 17, 2026, for approximately $475,138. The sale followed option exercises at $7.14-$9.08 per share. Consequently, Goin's direct stock holdings dropped to zero, though she retains 17,219 outstanding options."
datetime: "2026-06-22T21:07:07.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290479467.md)
  - [en](https://longbridge.com/en/news/290479467.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290479467.md)
---

# Palvella Therapeutics COO Kathleen Goin reports common stock sale worth $475,137.71

-   Palvella Therapeutics COO Kathleen Goin sold 4,302 common shares on June 17, 2026 at about $110.72 to $112.23. \* Sales followed option exercises for 4,302 shares at $7.14 to $9.08. \* Goin’s direct common stock holdings fell to zero. \* She reported 17,219 stock options remaining outstanding. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palvella Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-076460), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [PVLA.US](https://longbridge.com/en/quote/PVLA.US.md)

## Related News & Research

- [Palvella Therapeutics CEO joins Canaccord Genuity Growth Conference fireside chat](https://longbridge.com/en/news/294958978.md)
- [Palvella Therapeutics COO Kathleen Goin disposes of 4,302 common shares worth $642,194.57](https://longbridge.com/en/news/293070502.md)
- [Maze Therapeutics President, R&D and CMO Harold Bernstein disposes of USD 445,522 common shares](https://longbridge.com/en/news/295976091.md)
- [Catalyst4 acquires $50.07 million of MapLight Therapeutics common shares](https://longbridge.com/en/news/296276892.md)
- [Maze Therapeutics director Paula A. Johnson files initial beneficial ownership statement](https://longbridge.com/en/news/296144789.md)